THC
55
-3
WY
42
-6
AIV
43
-11
BSX
67
-2
BRK.B
49
-3
CTAS
37
-3
LEG
22
9
RHI
23
-2
TGNA
70
-2
AVY
51
-2
HP
34
6
SHW
46
-3
CTSH
42
-3
LLY
59
2
ETR
63
-2
LEN
15
-3
UHS
59
-4
DE
58
9
EIX
45
-2
VRTX
55
-3
THC
55
-3
WY
42
-6
AIV
43
-11
BSX
67
-2
BRK.B
49
-3
CTAS
37
-3
LEG
22
9
RHI
23
-2
TGNA
70
-2
AVY
51
-2
HP
34
6
SHW
46
-3
CTSH
42
-3
LLY
59
2
ETR
63
-2
LEN
15
-3
UHS
59
-4
DE
58
9
EIX
45
-2
VRTX
55
-3
Financhill
Back

Protalix BioTherapeutics 10K Form

Sell
44

PLX
Protalix BioTherapeutics

Last Price:
$2.48
Seasonality Move:
1.71%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLX News And Ratings

See the #1 stock for the next 7 days that we like better than PLX

PLX Financial Statistics

Sales & Book Value

Annual Sales: $53.4M
Cash Flow: $3.6M
Price / Cash Flow: 27.95
Annual Sales: $0.57
Price / Book: 4.5

Profitability

EPS (TTM): 0.03000
Net Income (TTM): $2.9M
Gross Margin: $29.1M
Return on Equity: 8.75%
Return on Assets: 3.66%

Protalix BioTherapeutics Earnings Forecast

Key Protalix BioTherapeutics Financial Ratios

  • The Gross Profit Margin over the past 27 years for PLX is 54.46%.
  • The Selling, General & Administrative Expenses for PLX have been equal to 22.83% of Gross Profit Margin.
  • The Research & Development expenses have been 24.29% of Revenue.
  • The Interest Expense is 36.22% of Operating Income.
  • The Net Earning history of PLX is 5.49% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 13 years.

Protalix BioTherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: PLX
CUSIP: 74365A
Website: protalix.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.34
Quick Ratio: 1.47

Price-to-Earnings

Trailing P/E Ratio: 62.25
Forward P/E Ratio: 0

PLX Technical Analysis vs Fundamental Analysis

Sell
44
Protalix BioTherapeutics (PLX) is a Sell

Is Protalix BioTherapeutics a Buy or a Sell?